Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria.
Aliment Pharmacol Ther. 2018 Apr;47(7):966-979. doi: 10.1111/apt.14485. Epub 2018 Feb 1.
Endoscopic band ligation (EBL) is used for primary (PP) and secondary prophylaxis (SP) of variceal bleeding. Current guidelines recommend combined use of non-selective beta-blockers (NSBBs) and EBL for SP, while in PP either NSBB or EBL should be used.
To assess (re-)bleeding rates and mortality in cirrhotic patients receiving EBL for PP or SP for variceal bleeding.
(Re-)bleeding rates and mortality were retrospectively assessed with and without concomitant NSBB therapy after first EBL in PP and SP.
Seven hundred and sixty-six patients with oesophageal varices underwent EBL from 01/2005 to 06/2015. Among the 284 patients undergoing EBL for PP, n = 101 (35.6%) received EBL only, while n = 180 (63.4%) received EBL + NSBBs. In 482 patients on SP, n = 163 (33.8%) received EBL only, while n = 299 (62%) received EBL + NSBBs. In PP, concomitant NSBB therapy neither decreased bleeding rates (log-rank: P = 0.353) nor mortality (log-rank: P = 0.497) as compared to EBL alone. In SP, similar re-bleeding rates were documented in EBL + NSBB vs EBL alone (log-rank: P = 0.247). However, EBL + NSBB resulted in a significantly lower mortality rate (log-rank: P<0.001). A decreased risk of death with EBL + NSBB in SP (hazard ratio, HR: 0.50; P<0.001) but not of rebleeding, transplantation or further decompensation was confirmed by competing risk analysis. Overall NSBB intake reduced 6-months mortality (HR: 0.53, P = 0.008) in SP, which was most pronounced in patients without severe/refractory ascites (HR: 0.37; P = 0.001) but not observed in patients with severe/refractory ascites (HR: 0.80; P = 0.567).
EBL alone seems sufficient for PP of variceal bleeding. In SP, the addition of NSBB to EBL was associated with an improved survival within the first 6 months after EBL.
内镜套扎(EBL)用于静脉曲张出血的一级(PP)和二级预防(SP)。目前的指南建议在 SP 中联合使用非选择性β受体阻滞剂(NSBB)和 EBL,而在 PP 中,应使用 NSBB 或 EBL。
评估接受 EBL 治疗 PP 或 SP 静脉曲张出血的肝硬化患者的再出血率和死亡率。
回顾性评估首次 EBL 后接受和不接受 NSBB 联合治疗的 PP 和 SP 患者的再出血率和死亡率。
2005 年 1 月至 2015 年 6 月期间,766 例食管静脉曲张患者接受了 EBL。在 284 例接受 EBL 治疗 PP 的患者中,n=101(35.6%)仅接受 EBL,而 n=180(63.4%)接受 EBL+NSBB。在 482 例 SP 患者中,n=163(33.8%)仅接受 EBL,而 n=299(62%)接受 EBL+NSBB。在 PP 中,与单独 EBL 相比,联合使用 NSBB 治疗既没有降低出血率(对数秩检验:P=0.353)也没有降低死亡率(对数秩检验:P=0.497)。在 SP 中,EBL+NSBB 与单独 EBL 相比,再出血率相似(对数秩检验:P=0.247)。然而,EBL+NSBB 导致死亡率显著降低(对数秩检验:P<0.001)。竞争风险分析证实,EBL+NSBB 在 SP 中降低了死亡风险(风险比,HR:0.50;P<0.001),但不会降低再出血、移植或进一步失代偿的风险。总体上,NSBB 摄入降低了 SP 患者的 6 个月死亡率(HR:0.53,P=0.008),在无严重/难治性腹水的患者中最为显著(HR:0.37;P=0.001),但在有严重/难治性腹水的患者中未见(HR:0.80;P=0.567)。
单独的 EBL 似乎足以用于 PP 静脉曲张出血。在 SP 中,EBL 联合 NSBB 可改善 EBL 后 6 个月内的生存率。